People · Operator
Named in public records as an officer, director or promoter · active 2014–2020 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Atreca, Inc. | — | Biotechnology | Series D+ | $222.2M | $5.2B | 2015 |
| Applied Therapeutics Inc. | — | Biotechnology | Series C | $189.2M | $1.0B | 2018 |
| Atea Pharmaceuticals, Inc. | — | Biotechnology | Series D+ | $175.9M | $4.4B | 2020 |
| Alzheon, Inc. | — | Biotechnology | Series D+ | $172.5M | $1.6B | 2014 |
| Rain Therapeutics Inc. | — | Biotechnology | Series C | $92.0M | $2.8B | 2020 |
| ESSA Pharma Inc. | — | Pharmaceuticals | Series B | $56.0M | $1.2B | 2016 |
| Cerus Endovascular Ltd | — | Biotechnology | Series A | $8.3M | $213.7M | 2017 |
Franklin Berger at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Franklin Berger on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jean-Pierre Sommadossi | 2 | 3 |
| BIHUA CHEN | 1 | 14 |
| Gerald Chan | 1 | 13 |
| Dennis Langer | 1 | 9 |
| Joel Marcus | 1 | 9 |
| David Wood | 1 | 8 |
| Scott Minick | 1 | 7 |
| Franz Hefti | 1 | 6 |
| Brian Atwood | 1 | 6 |
| William Robinson | 1 | 5 |
| Christopher Noel Dunn | 1 | 5 |
| Scott Requadt | 1 | 5 |
| Robert Silverman | 1 | 5 |
| David Nikodem | 1 | 4 |
| Michael Aceti | 1 | 4 |
| Lawrence Steinman | 1 | 4 |
| Fan Yu | 1 | 4 |
| John Simpson | 1 | 3 |
| David Parkinson | 1 | 3 |
| Frank Yu | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.